Clinical Trials
5 trialsNCT03016377 2025-10-27
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT02065869 2023-09-29
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03733249 2023-09-26
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03301168 2022-07-12
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Active not recruiting
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated